Skip to main content

Articles

Page 2 of 65

  1. Migraine is a brain disorder with recurrent headache attacks and altered sensory processing. Introvision is a self-regulation method based on mindfulness-like perception techniques, developed at the University...

    Authors: Monika Empl, Sonja Löser, Petra Spille, Agnieszka Rozwadowska, Ruth Ruscheweyh and Andreas Straube
    Citation: The Journal of Headache and Pain 2023 24:146
  2. The present study aimed to compare sex differences in the clinical manifestations related to dependence behaviors in medication-overuse headache (MOH).

    Authors: Yen-Feng Wang, Yi-Shiang Tzeng, Chia-Chun Yu, Yu-Hsiang Ling, Shih-Pin Chen, Kuan-Lin Lai, Wei-Ta Chen and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:145
  3. Monoclonal antibodies (mAbs) targeting the Calcitonin Gene-Related Peptide (CGRP) pathway are safe and effective treatments for migraine prevention. However, the high cost of these novel therapies has led to r...

    Authors: Ja Bin Hong, Kristin Sophie Lange, Mira Fitzek, Lucas Hendrik Overeem, Paul Triller, Anke Siebert, Uwe Reuter and Bianca Raffaelli
    Citation: The Journal of Headache and Pain 2023 24:144
  4. The 2030 Agenda for Sustainable Development sets out, through 17 Sustainable Development Goals (SDGs), a path for the prosperity of people and the planet. SDG 3 in particular aims to ensure healthy lives and p...

    Authors: Paolo Martelletti, Matilde Leonardi, Messoud Ashina, Rami Burstein, Soo-Jin Cho, Augustina Charway-Felli, David W. Dodick, Raquel Gil-Gouveia, Licia Grazzi, Christian Lampl, Antoinette MaassenVanDenBrink, Mia T. Minen, Dimos Dimitrios Mitsikostas, Jes Olesen, Mayowa Ojo Owolabi, Uwe Reuter…
    Citation: The Journal of Headache and Pain 2023 24:140
  5. BMP7 has been shown to have neuroprotective effects and to alleviate demyelination. However, its role in trigeminal neuralgia (TN) has not been well investigated. The current study aims to determine whether BM...

    Authors: Kai Chen, Xiaojin Wei, Ruixuan Wang, Lin Yang, Dingquan Zou and Yaping Wang
    Citation: The Journal of Headache and Pain 2023 24:143
  6. Chronic primary pain (CPP) is an intractable pain of unknown cause with significant emotional distress and/or dysfunction that is a leading factor of disability globally. The lack of a suitable animal model th...

    Authors: An-Ran Liu, Zhen-Jia Lin, Ming Wei, Yuan Tang, Hui Zhang, Xiang-Ge Peng, Ying Li, Yu-Fan Zheng, Zhi Tan, Li-Jun Zhou and Xia Feng
    Citation: The Journal of Headache and Pain 2023 24:141
  7. To determine specific resting-state network patterns underlying alterations in chronic migraine, we employed oscillatory connectivity and machine learning techniques to distinguish patients with chronic migrai...

    Authors: Fu-Jung Hsiao, Wei-Ta Chen, Yu-Te Wu, Li-Ling Hope Pan, Yen-Feng Wang, Shih-Pin Chen, Kuan-Lin Lai, Gianluca Coppola and Shuu-Jiun Wang
    Citation: The Journal of Headache and Pain 2023 24:139
  8. Amygdala, an essential element of the limbic system, has served as an important structure in pain modulation. There is still a lack of clarity about altered cerebral perfusion of amygdala in migraine. This stu...

    Authors: Xiaoyan Bai, Wei Wang, Xueyan Zhang, Zhangxuan Hu, Xue Zhang, Yingkui Zhang, Hefei Tang, Yaqing Zhang, Xueying Yu, Ziyu Yuan, Peng Zhang, Zhiye Li, Xun Pei, Yonggang Wang and Binbin Sui
    Citation: The Journal of Headache and Pain 2023 24:138
  9. The significance of hyperactive astrocytes in neuropathic pain is crucial. However, the association between medullary astrocytes and trigeminal neuralgia (TN)-related pain processing is unclear. Here, we exami...

    Authors: Elina KC, Jaisan Islam, Hyong Kyu Kim and Young Seok Park
    Citation: The Journal of Headache and Pain 2023 24:137
  10. Cluster headache is a severe and disabling primary headache disorder. Galcanezumab is a monoclonal antibody against calcitonin gene-related peptide and a preventive therapy for episodic cluster headache. Howev...

    Authors: Yooha Hong, Mi-Kyoung Kang, Heui-Soo Moon, Byung-Kun Kim and Soo-Jin Cho
    Citation: The Journal of Headache and Pain 2023 24:136
  11. Triptans are effective for many migraine patients, but some do not experience adequate efficacy and tolerability. The European Headache Federation (EHF) has proposed that patients with lack of efficacy and/or ...

    Authors: Ruth Ruscheweyh, Gudrun Gossrau, Thomas Dresler, Tobias Freilinger, Stefanie Förderreuther, Charly Gaul, Torsten Kraya, Lars Neeb, Victoria Ruschil, Andreas Straube, Jörg Scheidt and Tim Patrick Jürgens
    Citation: The Journal of Headache and Pain 2023 24:135
  12. Topiramate is a repurposed first-line treatment for migraine prophylaxis. The aim of this systematic review and meta-analysis is to critically re-appraise the existing evidence supporting the efficacy and tole...

    Authors: Bianca Raffaelli, David García-Azorín, Deirdre M. Boucherie, Faisal Mohammad Amin, Christina I. Deligianni, Raquel Gil-Gouveia, Sarah Kirsh, Christian Lampl, Simona Sacco, Derya Uluduz, Jan Versijpt, Antoinette MaassenVanDenBrink, Dena Zeraatkar, Margarita Sanchez-del-Rio and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:134
  13. Neuroimaging has revealed that migraine is linked to alterations in both the structure and function of the brain. However, the relationship of these changes with aging has not been studied in detail. Here we e...

    Authors: Rafael Navarro-González, David García-Azorín, Ángel L. Guerrero-Peral, Álvaro Planchuelo-Gómez, Santiago Aja-Fernández and Rodrigo de Luis-García
    Citation: The Journal of Headache and Pain 2023 24:133
  14. Although acute headache following COVID-19 vaccination is widely acknowledged, the long-term progression of these headaches remains poorly understood. Our objective was to identify various phenotypes of prolon...

    Authors: Arife Çimen Atalar, Ayşe Nur Özdağ Acarlı, Betül Baykan, Paolo Martelletti, Hayrunnisa Bolay, Mustafa Ertaş, Esme Ekizoğlu, Ömer Karadaş, Burcu Polat, Işıl Yazıcı Gençdal, David Garcia Azorin, Dimos Mitsikostas, Loukia Apostolakopoulou, Hamit Genç, Pınar Yalınay Dikmen, Esra Acıman Demirel…
    Citation: The Journal of Headache and Pain 2023 24:132
  15. Migraine is a disorder associated with neuropeptide release, pain and inflammation. Tau protein has recently been linked to inflammatory diseases and can be influenced by neuropeptides such as CGRP, a key neur...

    Authors: Lucas Hendrik Overeem, Bianca Raffaelli, Robert Fleischmann, Marie Süße, Antje Vogelgesang, Aleksandra Maleska Maceski, Athina Papadopoulou, Klemens Ruprecht, Wendy Su, Mirja Koch, Anke Siebert, Michal Arkuszewski, Nadia Tenenbaum, Jens Kuhle and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:130
  16. Novel disease-specific and mechanism-based treatments sharing good evidence of efficacy for migraine have been recently marketed. However, reimbursement by insurers depends on treatment failure with classic an...

    Authors: Christina I. Deligianni, Simona Sacco, Esme Ekizoglu, Derya Uluduz, Raquel Gil-Gouveia, Antoinette MaassenVanDenBrink, Raffaele Ornello, Margarita Sanchez-del-Rio, Uwe Reuter, Jan Versijpt, Tessa de Vries, Muizz Hussain, Dena Zeraatkar and Christian Lampl
    Citation: The Journal of Headache and Pain 2023 24:128
  17. Intranasal agents may be ideal for the treatment of migraine patients. Many new acute intranasal-specific therapies have been developed, but few of them have been directly compared. The aim of this network met...

    Authors: Guanglu Li, Shaojie Duan, Tiantian Zhu, Zhiying Ren, Hui Xia, Ziyao Wang, Lei Liu and Zunjing Liu
    Citation: The Journal of Headache and Pain 2023 24:129
  18. Headaches are the most common complaints among pediatric populations. Determining the cause and appropriate treatment for headaches may be challenging and costly, and the impact of headaches on the lives of pa...

    Authors: S. Ombashi, E. Tsangaris, A. G. Heeres, V. van Roey, R. F. Neuteboom, M. L. C. van Veelen-Vincent, K. Jansson, I. M. J. Mathijssen, A. F. Klassen and S. L. Versnel
    Citation: The Journal of Headache and Pain 2023 24:127
  19. In recent years, headache disorders have garnered significant attention as a pressing global health issue. This concern is especially pronounced in low- to middle-income countries and exhibits a notable increa...

    Authors: Xin-yu Li, Cheng-hao Yang, Jia-jie Lv, Hui Liu, Lu-yu Zhang, Min-yi Yin, Zhi-lin Guo and Ru-hong Zhang
    Citation: The Journal of Headache and Pain 2023 24:126

    The Correction to this article has been published in The Journal of Headache and Pain 2023 24:156

  20. Targeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that antagonize the CGRPergic system. Therefore, this review f...

    Authors: Alejandro Labastida-Ramírez, Edoardo Caronna, Cédric Gollion, Emily Stanyer, Austeja Dapkute, Diana Braniste, Hoda Naghshineh, Liga Meksa, Nino Chkhitunidze, Tamari Gudadze, Patricia Pozo-Rosich, Rami Burstein and Jan Hoffmann
    Citation: The Journal of Headache and Pain 2023 24:125
  21. There is a bidirectional link between sleep and migraine, however causality is difficult to determine. This study aimed to investigate this relationship using data collected from a smartphone application.

    Authors: Emily C. Stanyer, Jack Brookes, Jia Rong Pang, Alexandre Urani, Philip R. Holland and Jan Hoffmann
    Citation: The Journal of Headache and Pain 2023 24:123
  22. Although the involvement of calcitonin gene-related peptide (CGRP) in migraines is well-established, its specific role in investigating the aura phase, which often precedes the headache, remains largely unexpl...

    Authors: Haidar M. Al-Khazali, Håkan Ashina, Astrid Wiggers, Kathrine Rose, Afrim Iljazi, Rune Häckert Christensen, Henrik Winther Schytz, Faisal Mohammad Amin and Messoud Ashina
    Citation: The Journal of Headache and Pain 2023 24:124
  23. Migraine, a complex brain disorder, is regarded as a possible clinical manifestation of brain energy dysfunction. The trigeminovascular system is considered the basis for the pathogenesis of migraine, hence we...

    Authors: Wei Xie, Ruibing Li, Wenjing Tang, Zhenjie Ma, Shuai Miao, Chenhao Li, Chunxiao Yang, Bozhi Li, Tao Wang, Zihua Gong, Yue Zhou and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2023 24:122
  24. Treatment for cluster headache is currently based on a trial-and-error approach. The available preventive treatment is unspecific and based on few and small studies not adhering to modern standards. Therefore,...

    Authors: Nunu Laura Timotheussen Lund, Anja Sofie Petersen, Rolf Fronczek, Jacob Tfelt-Hansen, Andrea Carmine Belin, Tore Meisingset, Erling Tronvik, Anna Steinberg, Charly Gaul and Rigmor Højland Jensen
    Citation: The Journal of Headache and Pain 2023 24:121
  25. Migraine is a highly prevalent primary headache disorder and a leading cause of disability. Difficulties in access to care during diagnostic and therapeutic journey contribute to the disease burden. Several ta...

    Authors: Gloria Vaghi, Roberto De Icco, Cristina Tassorelli, Peter J. Goadsby, Teófila Vicente-Herrero and Elena Ruiz de la Torre
    Citation: The Journal of Headache and Pain 2023 24:120
  26. Headache disorders are widely prevalent and pose a considerable economic burden on individuals and society. Globally, misdiagnosis and inadequate treatment of primary headache disorders remain significant chal...

    Authors: Huanxian Liu, Ming Dong, Kaiming Liu, Zhihua Jia, Wei Gui, Yingying Cheng, Yudan Lv, Kang Qu, Hongru Zhao, Jianjun Chen, Dan Zhang, Zhiliang Fan, Xiaosu Yang, Dongmei Hu, Hongyan Xie, Mingxin Li…
    Citation: The Journal of Headache and Pain 2023 24:119
  27. Central sensitisation is an important mechanism in migraine chronification. It is presumed to occur in second and third order neurons sequentially, resulting in an analogous spatial distribution of cutaneous a...

    Authors: Judith A. Pijpers, Dennis A. Kies, Erik W. van Zwet, Irene de Boer and Gisela M. Terwindt
    Citation: The Journal of Headache and Pain 2023 24:118
  28. Adipokines, including adiponectin, are implicated in nociceptive pain; however, the underlying cellular and molecular mechanisms remain unknown.

    Authors: Yuan Zhang, Yuan Wei, Tingting Zheng, Yu Tao, Yufang Sun, Dongsheng Jiang and Jin Tao
    Citation: The Journal of Headache and Pain 2023 24:117
  29. Data are limited regarding the combined impact of headache frequency and failure of preventive medication (efficacy and/or tolerability) on the humanistic/economic burden of migraine.

    Authors: Dawn C. Buse, Patricia Pozo-Rosich, Laure Dupont-Benjamin, Bridget L. Balkaran, Lulu Lee, Adam Jauregui, Pranav Gandhi, Mousam Parikh and Uwe Reuter
    Citation: The Journal of Headache and Pain 2023 24:115
  30. Headache is one of the most common neurological symptoms. Many previous studies have indicated a relationship between primary headaches and alcohol. Drinking has been associated with increased risk of tension-...

    Authors: Bartłomiej Błaszczyk, Marcin Straburzyński, Mieszko Więckiewicz, Sławomir Budrewicz, Piotr Niemiec, Martyna Staszkiewicz and Marta Waliszewska-Prosół
    Citation: The Journal of Headache and Pain 2023 24:116
  31. Cluster headache (CH) is a primary headache disorder which is characterized by circadian timing of headache attacks, usually at nighttime, in around two thirds of patients. Patients with CH often report sleep ...

    Authors: Caroline Ran, Felicia Jennysdotter Olofsgård, Anna Steinberg, Christina Sjöstrand, Elisabet Waldenlind, Anna Dahlgren and Andrea Carmine Belin
    Citation: The Journal of Headache and Pain 2023 24:114
  32. Primary headache disorders are a group of highly prevalent and disabling neurological diseases that mainly consist of migraine and tension-type headache (TTH). A previous study showed that the burden of headac...

    Authors: Rongguang Ge, Jie Chang and Yongjun Cao
    Citation: The Journal of Headache and Pain 2023 24:110
  33. While previous genome-wide association studies (GWAS) have identified multiple risk variants for migraine, there is a lack of evidence about how these variants contribute to the development of migraine. We emp...

    Authors: Shuang-jie Li, Jing-jing Shi, Cheng-yuan Mao, Chan Zhang, Ya-fang Xu, Yu Fan, Zheng-wei Hu, Wen-kai Yu, Xiao-yan Hao, Meng-jie Li, Jia-di Li, Dong-rui Ma, Meng-nan Guo, Chun-yan Zuo, Yuan-yuan Liang, Yu-ming Xu…
    Citation: The Journal of Headache and Pain 2023 24:111
  34. It is unknown whether new daily persistent headache (NDPH) is a single disorder or heterogenous group of disorders, and whether it is a unique disorder from chronic migraine and chronic tension-type headache. ...

    Authors: Sanjay Cheema, Anker Stubberud, Khadija Rantell, Parashkev Nachev, Erling Tronvik and Manjit Matharu
    Citation: The Journal of Headache and Pain 2023 24:109
  35. Calcitonin gene-related peptide (CGRP) is involved in migraine pathophysiology and blood pressure regulation. Although clinical trials have established the cardio-cerebrovascular safety profile of anti-CGRP tr...

    Authors: Kaicheng Wang, Brenda T. Fenton, Vinh X. Dao, Alexander B. Guirguis, Sarah E. Anthony, Melissa Skanderson and Jason J. Sico
    Citation: The Journal of Headache and Pain 2023 24:108
  36. Authors: Adrian Scutelnic, Hristina Drangova, Antonia Klein, Nedelina Slavova, Morin Beyeler, Julian Lippert, Norbert Silimon, Thomas R. Meinel, Marcel Arnold, Urs Fischer, Franz Riederer, Heinrich P. Mattle, Simon Jung and Christoph J. Schankin
    Citation: The Journal of Headache and Pain 2023 24:107

    The original article was published in The Journal of Headache and Pain 2023 24:100

  37. There is increasing evidence from human and animal studies that cortical spreading depression (CSD) is the neurophysiological correlate of migraine aura and a trigger of migraine pain mechanisms. The mechanism...

    Authors: Marina Vitale, Angelita Tottene, Maral Zarin Zadeh, KC Brennan and Daniela Pietrobon
    Citation: The Journal of Headache and Pain 2023 24:105

    The Correction to this article has been published in The Journal of Headache and Pain 2023 24:171

  38. Migraine is a cyclic, neurosensory disorder characterized by recurrent headaches and altered sensory processing. The latter is manifested in hypersensitivity to visual stimuli, measured with questionnaires and...

    Authors: Angela Marti-Marca, Adrià Vilà-Balló, Xim Cerda-Company, Nara Ikumi, Marta Torres-Ferrus, Edoardo Caronna, Victor J. Gallardo, Alicia Alpuente, Mireia Torralba Cuello, Salvador Soto-Faraco and Patricia Pozo-Rosich
    Citation: The Journal of Headache and Pain 2023 24:104
  39. The phase 3 randomized PERSIST study demonstrated the efficacy and tolerability of galcanezumab, a humanized anti-calcitonin gene-related peptide (CGRP) monoclonal antibody for prevention of episodic migraines...

    Authors: Jiying Zhou, Lianmei Zhong, Debashish Chowdhury, Kirill Skorobogatykh, Guogang Luo, Xiaosu Yang, Mingjie Zhang, Lingli Sun, Hui Liu, Chenxi Qian and Shengyuan Yu
    Citation: The Journal of Headache and Pain 2023 24:103
  40. Individuals using onabotulinumtoxinA as a preventive migraine treatment often use acute treatments for breakthrough attacks. Data on real-world effectiveness of the small-molecule calcitonin gene–related pepti...

    Authors: Aubrey Manack Adams, Susan Hutchinson, Ella Engstrom, Nicolai D. Ayasse, Daniel Serrano, Linda Davis, Katherine Sommer, Janette Contreras-De Lama and Richard B. Lipton
    Citation: The Journal of Headache and Pain 2023 24:102
  41. To date, real-world evidence on persistence to anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies (mAbs) or onabotulinumtoxinA have excluded eptinezumab. This retrospective cohort study was...

    Authors: Larry Charleston IV, Brian Talon, Christine Sullivan, Carlton Anderson, Steven Kymes, Stephane A. Regnier, Seema Soni-Brahmbhatt and Stephanie J. Nahas
    Citation: The Journal of Headache and Pain 2023 24:101
  42. Given the similar presentation of migraine aura and acute ischemic stroke, advancing patient age might change the characteristics of migraine with aura (MA) and be clinically important. Clinical data, however,...

    Authors: Adrian Scutelnic, Hristina Drangova, Antonia Klein, Nedelina Slavova, Morin Beyeler, Julian Lippert, Norbert Silimon, Thomas R. Meinel, Marcel Arnold, Urs Fischer, Franz Riederer, Heinrich P. Mattle, Simon Jung and Christoph J. Schankin
    Citation: The Journal of Headache and Pain 2023 24:100

    The Correction to this article has been published in The Journal of Headache and Pain 2023 24:107

  43. The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP) pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved preventive migraine treatment. Although t...

    Authors: Jean Schoenen, Annelies Van Dycke, Jan Versijpt and Koen Paemeleire
    Citation: The Journal of Headache and Pain 2023 24:99
  44. Whether migraine is related to the risk of cardiovascular diseases (CVDs) remains unclear. Therefore, we conducted a longitudinal follow-up study to address the association between migraine and the development...

    Authors: Mi Jung Kwon, Hyo Geun Choi, Yoo Hwan Kim, Joo-Hee Kim, Hyun Taek Rim, Heui Seung Lee, Jae Keun Oh, In Bok Chang, Joon Ho Song and Ji Hee Kim
    Citation: The Journal of Headache and Pain 2023 24:98
  45. In idiopathic intracranial hypertension (IIH), certain MRI features are promising diagnostic markers, but whether these have prognostic value is currently unknown.

    Authors: Gabriel Bsteh, Wolfgang Marik, Nik Krajnc, Stefan Macher, Christoph Mitsch, Philip Pruckner, Klaus Novak, Christian Wöber and Berthold Pemp
    Citation: The Journal of Headache and Pain 2023 24:97